George Vlasuk, chief executive of Sirtris, said in a phone interview that the complication is common in multiple myeloma patients and 「may or may not be related to」 the drug.
Sirtris的首席执行官GeorgeVlasuk在一个电话采访中说并发癥对于多发性骨髓瘤很普遍,「可能会也可能不会」是和药物有关。
The researchers deployed a combination of peptides—small pieces of protein—that are known to be specific to multiple myeloma cells and are important for their survival.
这些研究人员将肽(蛋白质片段)化合物作为研究重点,该化合物为多发性骨髓瘤细胞所独有,对于这种细胞的生存至关重要。
Multiple myeloma is a cancer of blood plasma cells.
多发性骨髓瘤是一种血浆细胞癌癥。
The lesson to be learned from the present case is that a transient plasma cell dyscrasia may present like multiple myeloma in the setting of heavy immunosuppression after organ transplantation.
从这个病例中得到的教训是,在器官移植后的严重免疫抑制状况下,暂时性血细胞恶液质可以有类似多发性骨髓瘤样的表现。
Leukemia, lymphoma or myeloma might have stolen your childlike belief that this life will go on forever.
孩提时代,你相信生活会直到永远,而白血病,淋巴瘤或是骨髓瘤可能会摧毁你的这种信念。
In the other report, Celgene Inc. 's Revlimid doubled the number of myeloma patients whose disease remained in remission three years after treatment began, compared with those on placebo.
在另外一篇报告里,Celgene公司的Revlimid药在开始服用后的三年内脊髓瘤患者处于缓解期的人数比服用安慰剂组的数量增加了一倍。
Still, when most people hear a diagnosis of leukemia, lymphoma or myeloma they respond with shock, fear and disbelief.
还有,当大多数人听到的诊断早幼粒细胞白血病,淋巴瘤或多发性骨髓瘤,他们的反应是惊愕,恐惧和难以置信。
Objective To investigate the clinical features in patients with multiple myeloma (MM) and the significance of bone marrow cell morphology in MM diagnosis.
目的:探讨多发性骨髓瘤(MM)的主要临床特点以及骨髓细胞形态学在MM诊断中的作用。
Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.
Revlimid和类固醇地塞米松联合用药被批準用于多发性脊髓瘤和罕见病 骨髓增生异常综合征的治疗。 其2009年的销售额为17亿美元。
Multiple myeloma is a blood cancer that typically strikes much later in life.
多发性肿瘤是一种血癌,通常在晚期才发作。
The fresh spleen cell was used for fusion with myeloma cell.
新鲜的脾细胞用来与骨髓瘤细胞进行融合。
Research funded by the multiple myeloma Re — search Foundation at a small biotech led to a promising new drug for multiple myeloma, a cancer of plasma cells in bones.
MultipleMyeloma研究基金会资助了一家小型生物科技企业的研究,发现了一种很有前途的新药,能够治疗多发性骨髓瘤,一种骨头中原生质细胞的癌癥。
At low power, the abnormal plasma cells of multiple myeloma fill the marrow.
低倍镜显示多发性骨髓瘤异常浆细胞弥漫浸润骨髓。